Agenus Inc. (AGEN) Reports 51% Survived 18 Months on BOT+BAL
Agenus Inc. reported that 51% of 123 patients with a specific type of colorectal cancer survived at least 18 months on its BOT+BAL treatment, with an estimated 59% of those alive at three years. This is a post-hoc analysis of prior Phase 1b results, not a new trial.
How this was made

The 30-second read
Why it matters
It provides additional survival durability statistics (18-month and estimated 3-year survival among responders), but the lack of a new controlled trial readout limits how much it can change near-term expectations.
Market read
Supportive but non-prospective survival durability data may modestly bolster sentiment, yet it is unlikely to drive a major repricing without prospective Phase 3 results.
What to watch
Traders may discount the signal until the company’s prospective Phase 3 ROBBIN strategy reports, and may also weigh the lack of active liver metastases as a selection effect.
Background
The piece is a post-hoc analysis of previously reported Phase 1b results for BOT+BAL in refractory MSS metastatic colorectal cancer without active liver metastases.
Ticker impact
Agenus reports a post-hoc analysis where 51% of 123 refractory MSS metastatic colorectal cancer patients survived at least 18 months on BOT+BAL.
Likely limited near-term upside as traders may view the results as supportive yet non-prospective, reducing conviction versus prospective Phase 3 evidence.
The article provides additional survival percentages but states it is post-hoc of previously reported Phase 1b results, implying lower incremental decision value than a new trial endpoint or regulatory milestone.
Market effects
Adds incremental sentiment for immuno-oncology/biotech trial durability narratives, but without prospective Phase 3 confirmation it is unlikely to re-rate the broader sector materially.
No clear regional market linkage beyond US biotech sentiment.
Limited global relevance since the update is a company-specific post-hoc analysis rather than a cross-market regulatory or approval event.
Counterpoint
Because the analysis is post-hoc and limited to patients without active liver metastases, the survival durability may not generalize and could be overstated versus prospective endpoints.
Key entities
- companyAgenus Inc.
Subject of the article, reporting post-hoc survival outcomes for BOT+BAL in a defined MSS colorectal cancer subgroup.
- therapyBOT+BAL
Treatment regimen evaluated in the Phase 1b dataset underlying the post-hoc analysis.
- clinical programROBBIN strategy
Prospective Phase 3 strategy referenced as the larger catalyst needed for stronger read-through.
